Hyperkalemia and Heart Failure: Identifying Risks and Exploring Treatment Options
Expiration Date: February 2019
1.0 Contact Hour ANCC
- Describe the prevalence and causes of hyperkalemia, its association with adverse clinical outcomes and patient populations at risk for developing hyperkalemia.
- Discuss the development of hyperkalemia in HF patients who are taking RAAS inhibitors.
- Explain the relationship of hyperkalemia-related discontinuation/suboptimal dosing of RAAS inhibitors in heart failure patients to increased cardiovascular risk
- Recognize goals and implement prudent strategies for managing acute, subacute/intermediate, and chronic hyperkalemia
- Assess the mechanisms of action, pharmacodynamic profiles, efficacy, and safety of potassium bind for the treatment of hyperkalemia in patients with HF.
- Recognize the roles and clinical settings for new and emerging agents for treatment of hyperkalemia in heart failure patients.
REQUIREMENT FOR SUCCESSFUL COMPLETION
- Attendance at the entire event.
- Complete/submit evaluation form.
- Access and print your certificate.
Maureen Flattery, NP
Planning committee members have no conflicts of interest that relate to this activity.
The following faculty have no conflicts of interest that relate to this activity
Chris Bell, ACNP
The faculty below has disclosed the following
Paul Hauptman, MD, Grants: Alnylam, NHLBI, Relypsa, BMS, Speaker Bureau: Otsuka, Relypsa, Consultant: St Jude Medical, Sunshine Medical, Corvia
This activity is provided by the American Association of Heart Failure Nurses (AAHFN).
The American Association of Heart Failure Nurses (AAHFN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Commercial support for this activity has been provided by CZ Pharma.